Classification and diagnosis of immune-mediated rheumatic diseases
How can we classify immune-mediated rheumatic diseases? Why is it particularly important to diagnose and treat them early?
How can we classify immune-mediated rheumatic diseases? Why is it particularly important to diagnose and treat them early?
What clinical features and laboratory test results suggest idiopathic inflammatory myopathy?
The number of indications for the use of biologic drugs in rheumatic diseases is growing. Which classes of biologics are currently used?
Are biologic drugs used in the treatment of macrophage activation syndrome?
How to manage a patient with macrophage activation syndrome?
Are atypical fractures a frequent adverse effect of bisphosphonates? What drugs should be used in such situations?
What is the relation between fractures and quality of life, morbidity, and mortality?
When should we suspect macrophage activation syndrome in patients with adult-onset Still disease?
Which classes of drugs should be avoided in elderly patients because of increased risk of fractures? Does this include selective serotonin reuptake inhibitors (SSRIs) commonly used to treat depression?